Misoprostol therapeutics revisited

• Published in: Pharmacotherapy Vol. 21; no. 1; p. 60
• Main Authors: Davies, N M, Longstreth, J, Jamali, F
• Format: Journal Article
• Language: English
• Published: United States 01.01.2001
• Subjects: Animals; Anti-Inflammatory Agents, Non-Steroidal - adverse effects; Anti-Ulcer Agents - administration & dosage; Anti-Ulcer Agents - pharmacokinetics; Anti-Ulcer Agents - pharmacology; Anti-Ulcer Agents - therapeutic use; Humans; Misoprostol - administration & dosage; Misoprostol - pharmacokinetics; Misoprostol - pharmacology; Misoprostol - therapeutic use; Stomach Ulcer - chemically induced; Stomach Ulcer - prevention & control
• ISSN: 0277-0008
• DOI: 10.1592/phco.21.1.60.34442

Misoprostol, a prostaglandin E1 analog, is a racemate of four stereoisomers. On administration it rapidly de-esterifies to its active form, misoprostolic acid. Misoprostolic acid is 85% albumin bound and has a half-life of approximately 30 minutes. It is excreted in urine as inactive metabolites. No significant drug interactions have been reported. Besides its gastrointestinal protective and uterotonic activities, misoprostol regulates various immunologic cascades. It inhibits platelet-activating factor and leukocyte adherence, and modulates adhesion molecule expression. It protects against gut irradiation injury, experimental gastric cancer, enteropathy, and constipation. It improves nutrient absorption in cystic fibrosis. Misoprostol has utility in acetaminophen and ethanol hepatotoxicity, hepatitis, and fibrosis. It is effective in asthmatics and aspirin-sensitive asthmatic and allergic patients. It lowers cholesterol and severity of peripheral vascular diseases, prolongs survival of cardiac and kidney transplantation, synergizes cyclosporine, and protects against cyclosporine-induced renal damage. It works against drug-induced renal damage, interstitial cystitis, lupus nephritis, and hepatorenal syndrome. It is useful in periodontal disease and dental repair. Misoprostol enhances glycosoaminoglycan synthesis in cartilage after injury. It prevents ultraviolet-induced cataracts and reduces intraocular pressure in glaucoma and ocular hypertension. It synergizes antiinflammatory and analgesic effects of diclofenac or colchicine and has been administered to treat trigeminal neuralgic pain. It reduces chemotherapy-induced hair loss and recovery time from burn injury, and is effective in treating sepsis, multiple sclerosis, and pancreatitis.